Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Kalamazoo, Michigan 49007


The primary purpose of this study is to assess the single-dose bioavailability of AKB-6548 with ferrous sulfate relative to AKB-6548 in healthy volunteers.


Inclusion Criteria: - Healthy male subjects 18 to 55 years of age with a body mass index between 18 and 30 kg/m2 - Participants and their partners must use a highly effective form of contraception during the study and for 1 month following discharge from the Clinical Research Unit (CRU) - Subjects must discontinue all iron preparations for 14 days prior to study drug administration Exclusion Criteria: - Current or past history of cardiovascular, cerebrovascular, pulmonary, renal or liver disease - Positive serology results for HBsAg, HCV, and HIV at Screening - Renal impairment (estimated glomerular filtration rate (eGFR) of <65mL/min) - Known active cancer (except non-melanoma skin cancer) or history of chemotherapy use within the previous 24 months - Current or past history of gastric or duodenal ulcers or other diseases of the GI tract (including gastric bypass surgeries) that could interfere with absorption of study drug - Subjects with a known history of smoking and/or have used nicotine or nicotine-containing products within the past 6 months



Primary Contact:

Study Chair
Akshay Buch
Akebia Therapeutics, Inc.

Backup Contact:


Location Contact:

Kalamazoo, Michigan 49007
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.